EFFICACY OF DABRAFENIB AND TRAMETINIB IN THE TREATMENT OF DISSEMINATED MELANOMA WITH BRAF MUTATION


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Disseminated melanoma - a malignant neoplasm with high mortality rates in the world. The efficacy of chemotherapy remains low. The discovery of BRAF mutation and subsequent use of BRAF-inhibitors has allowed to significantly improve the outcomes in patients with disseminated melanoma. The use of combination of BRAF-inhibitors and MEK-inhibitors showed higher efficacy than monotherapy.

Full Text

Restricted Access

About the authors

M. E Abramov

FSBI “RORC n.a. N.N. Blokhin" of RMH

PhD, Senior Scientist at the Department of Chemotherapy and Combined Treatment of Malignant Tumors Moscow

O. O Gordeeva

FSBI “RORC n.a. N.N. Blokhin" of RMH

Moscow

G. V Vyshinskaya

FSBI “RORC n.a. N.N. Blokhin" of RMH

Moscow

References

  1. Статистика злокачественных новообразований в России и странах СНГ в 2012 г. / Под ред. М.И. Давыдова, Е.М. Аксель. М., 2014. 226 с.
  2. Злокачественные новообразования в России в 2014 году (заболеваемость и смертность) / Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. М., 2016.
  3. Berwick M., Erdei E., Hay, J. Melanoma epidemiology and public health. Dermatol. Clin. 2009;27:205-14.
  4. Luke J.J., Schwartz G.K. Chemotherapy in the Management of Advanced Cutaneous Malignant Melanoma. Clin. Dermatol. 2013;31(3): 290-97.
  5. Ives N.J., Stowe R.L., Lorigan P., Wheatley K. ChemotherapyComparedWithBiochemotherapy for the Treatment of Metastatic Melanoma: A Meta-Analysis of 18 Trials Involving 2,621 Patients J. Clin. Oncol. 2007;25:5426-34.
  6. Alexandrov L.B., Nik-Zainal S., Wedge D.C., et al. Signatures of mutational processes in human cancer. Nature. 2013;500(7463):415-21.
  7. Chapman P.B., Hauschild A., Robert C., Haanen J.B., Ascierto P., Larkin J., Dummer R., Garbe C., Testori A., Maio M., Hogg D., Lorigan P., Lebbe C., Jouary T., Schadendorf D., Ribas A., O'Day S.J., Sosman J.A., Kirkwood J.M., Eggermont A.M., Dreno B., Nolop K., Li J., Nelson B, Hou J., Lee R.J., Flaherty K.T., McArthur G.A. Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation. N. Engl. J. Med. 2010;364(26):2507-16.
  8. Menzies A.M., Haydu L.E., Visintin L., Carlino M.S., Howle J.R., Thompson J.F., et al. Distinguishing clinicopathologic features of patients with V600E and V600K BRAF-mutant metastatic melanoma. Clin. Jakob. J. ASCO 2011. Abstract 8500. Cancer Res. 2012;18:3242-49.
  9. Falchook G.S, Long G.V., Kurzrock R., Kim K.B., Arkenau T.H., Brown M.P., Hamid O., Infante J.R., Millward M., Pavlick A.C., O'Day S.J., Blackman S.C., Curtis C.M., Lebowitz P., Ma B., Ouellet D., Kefford R.F. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet. 2012;379: 1893-901.
  10. Ascierto P.A., Minor D., Ribas A., Lebbe C., O'Hagan A., Arya N., Guckert M., Schadendorf D., Kefford R.F., Grob J.J., Hamid O., Amaravadi R., Simeone E., Wilhelm T., Kim K.B., Long G.V., Martin A.M., Mazumdar J., Goodman V.L., Trefzer U. Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma. J. Clin.Oncol. 2013;31:3205-11.
  11. Long G.V., Trefzer U., Davies M.A., Kefford R.F., Ascierto P.A., Chapman P.B., Puzanov I., Hauschild A., Robert C., Algazi A., Mortier L., Tawbi H., Wilhelm T., Zimmer L., Switzky J., Swann S., Martin A.M., Guckert M., Goodman V., Streit M., Kirkwood J.M., Schadendorf D. Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet. Oncol. 2012;13:1087-95.
  12. Grob J.-J., Amonkar M.M., Martin-Algarra S., Demidov L.V., Goodman V., Grotzinger K., Haney P., Kämpgen E., Karaszewska B., Mauch C., Miller W.H. Jr., Millward M., Mirakhur B., Rutkowski P., Chiarion-Sileni V., Swann S., Hauschild A. Patient perception of the benefit of a BRAF inhibitor in metastatic melanoma: quality-of-life analyses of the BREAK-3 study comparing dabrafenib with dacarbazine. Ann. Oncol. 2014;25:1428-36.
  13. Falanga A., Mandala M., et al. Predictive Value For Disease Progression Of Thrombin Generation and D-Dimer Levels In Melanoma Patients Receiving BRAF Inhibitor. Therapy. Blood. 2013;122(21).
  14. Infante J.R., Fecher L.A., Falchook G.S., Nallapareddy S., Gordon M.S., Becerra C., DeMarini D.J., Cox D.S., Xu Y., Morris S.R., Peddareddigari V.G., Le N.T., Hart L., Bendell J.C., Eckhardt G., Kurzrock R., Flaherty K., Burris H.A. 3rd, Messersmith W.A. Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial. Lancet Oncol. 2012; 13(8):773-81.
  15. Kim K.B., Lewis K., Pavlick A., Infante J.R., Ribas A., Sosman J.A., et al. A phase II study of the MEK1/MEK2 inhibitor GSK1120212 in metastatic BRAF-V600E or K mutant cutaneous melanoma patients previously treated with or without a BRAF inhibitor [abstract]. Pigment Cell Melanoma Res. 2011;Suppl. 24LBA1-3:1021.
  16. Flaherty K.T., Robert C., Hersey P., Nathan P., Garbe C., Milhem M., Demidov L.V., Hassel J.C., Rutkowski P., Mohr P., Dummer R., Trefzer U., Larkin J.M., Utikal J., Dreno B., Nyakas M., Middleton M.R., Becker J.C., Casey M., Sherman L.J., Wu F.S., Ouellet D., Martin A.M., Patel K., Schadendorf D. Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma. N. Engl. J. Med. 2012;367(2):107-14.
  17. Long G.V., Stroyakovskiy D., Gogas H., et al. Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma. N. Engl. J. Med. 2014; 371:1877-88.
  18. Robert C., Karaszewska B., Schachter J., Rutkowski P., Mackiewicz A., Stroiakovski D., Lichinitser M., Dummer R., Grange F., Mortier L., Chiarion-Sileni V., Drucis K., Krajsova I., Hauschild A., Lorigan P., Wolter P., Long G.V., Flaherty K., Nathan P., Ribas A., Martin A.M., Sun P., Crist W., Legos J., Rubin S.D., Little S.M., Schadendorf D. Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib. N. Engl. J. Med. 2015; 372(1):30-9.
  19. Zeynep Eroglu and Antoni Ribas Combination therapy with BRAF and MEK inhibitors for melanoma: latest evidence and place in therapy Ther. Adv Med Oncol. 2016;8(1):48-56.
  20. Menzies A.M., et al. Characteristics of pyrexia in BRAFV600E/K metastatic melanoma patients treated with combined dabrafenib and tra-metinib in a phase I/II clinical trial Ann. Oncol. 2015;26(2):415-21.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies